Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: August 16, 2024
Context: The Company entered into a "Capital on Demand" Sales Agreement with JonesTrading Institutional Services LLC to facilitate the potential sale of ordinary shares.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the terms of a new securities offering agreement.
- Maximum Offering Size: Up to $2,524,437 in gross proceeds.
- Commission Fee: 3.0% of gross proceeds payable to the Sales Agent.
- Securities Type: Ordinary shares, no par value.
Material Changes
The primary material event is the execution of the Sales Agreement on August 16, 2024. This agreement allows the Company to sell shares "at the market" via the Sales Agent. The Company is not obligated to sell any shares under this agreement.
Guidance, Outlook, and Risks
Management Commentary: The Company may offer and sell shares from time to time based on its instructions, including price, time, or size limits. Sales will be made at prevailing market prices or related prices.
Termination: The offering will terminate upon the earlier of the termination of the Sales Agreement or mutual agreement by the parties.
Risks and Contingencies:
- Sales are subject to customary closing conditions and the Sales Agent's commercially reasonable efforts.
- The Company must reimburse the Sales Agent for certain specified expenses.
- The filing explicitly states it does not constitute an offer to sell in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current market price of NeuroSense Therapeutics ordinary shares to assess potential dilution impact.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific price limits or volume restrictions.
- Check subsequent filings to determine if and when shares were actually sold under this agreement.
- Confirm the Company's current cash position to understand the necessity of this capital raise.